Microbiome Gut Brain Axis Therapy is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Property |
Value |
| Category |
Emerging Therapy |
| Target |
Gut microbiome composition |
| Diseases |
Alzheimer's Disease, Parkinson's Disease, ALS |
| Key Items |
FMT, Probiotics, Prebiotics, Postbiotics |
| Mechanism |
Bidirectional neural-immune-metabolic signaling |
The gut-brain axis is a bidirectional communication network linking emotional and cognitive centers of the brain with peripheral intestinal functions. This communication occurs via neural, endocrine, immunological, and metabolic pathways. Microbiome-based therapies aim to modulate this axis to treat neurodegenerative diseases. The gut contains 100 trillion microorganisms that profoundly influence brain function. ## The Gut-Brain Axis
- Vagus nerve: Primary parasympathetic connection between gut and brain
- Enteric nervous system: "Second brain" with 500 million neurons
- Neurotransmitter production: 95% of serotonin produced in gut
- HPA axis: Cortisol-mediated stress response
- SCFA production: Butyrate, propionate, acetate from bacterial fermentation
- Bile acid signaling: FXR and TGR5 receptors in brain
- GALT: Gut-associated lymphoid tissue
- Cytokine signaling: TNF-α, IL-1β, IL-6
- Mucosal immunity: IgA secretion ## Dysbiosis in Neurodegeneration
- Reduced microbial diversity
- Increased pro-inflammatory bacteria (Proteobacteria)
- Decreased anti-inflammatory bacteria (Bifidobacterium)
- Elevated LPS in brain tissue
- Altered SCFA levels
- Constipation precedes motor symptoms by years
- α-Synuclein deposition in enteric nervous system
- Reduced Faecalibacterium
- Increased Escherichia/Shigella
- Vagotomy reduces PD risk
- Altered microbiome composition
- Reduced butyrate producers
- Increased pro-inflammatory species ## Therapeutic Approaches
- Restores healthy microbiome
- Shows promise in PD motor symptoms
- Ongoing trials in AD
- Safety considerations in elderly
- Single strain: Lactobacillus, Bifidobacterium
- Multi-strain: Combinations with psychobiotics
- Psychobiotics: Mood and cognition effects
- Targeted: Strain-specific applications
- Dietary fiber: Inulin, FOS, GOS
- Resistant starch: Type 2 and 4
- Polyphenols: Enhance beneficial bacteria
- SCFAs: Butyrate, propionate supplementation
- Bacterial lysates: Immune modulation ## Clinical Evidence
| Study |
Intervention |
Outcome |
| Sampson et al. 2016 |
GF mice + AD feces |
Cognitive impairment |
| Bedarf et al. 2017 |
FMT in PD |
Improved motor scores |
| Torti et al. 2022 |
Probiotic in AD |
Cognitive improvement |
| Kuang et al. 2022 |
FMT in PD |
Long-term safety |
- Individual variability: Personalized microbiomes
- Strain specificity: Not all probiotics equal
- Delivery: Ensuring brain effects
- Safety: Immunocompromised patients
- Standardization: Strain identification
The study of Microbiome Gut Brain Axis Therapy has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.